Teva manufactures and sells generic drugs, making it one of the largest generic drug suppliers in the US by prescription volume. It also sells branded specialty medicines focused on neurology and immunology (including drugs for multiple sclerosis and migraines), as well as biosimilars. Customers include retail pharmacies, hospitals, and healthcare systems across North America, Europe, Japan, Russia, and Israel. Additional revenue comes from selling active pharmaceutical ingredients to other drugmakers, contract manufacturing, and through Anda, a US distributor that wholesales generics and specialty drugs to pharmacies. Generics dominate the business; North America accounts for roughly half of total sales.
Employees32,842IPOFeb 16, 1982HQ124 Dvora HaNevi’a Street, Tel Aviv, ISR, 6944020
to
Financials
Profitability
Metric
Current
Margins
Gross Margin
52.5%
Operating Margin
18.8%
EBITDA Margin
15.0%
Net Margin
4.1%
OCF Margin
11.0%
FCF Margin
7.8%
Returns on Capital
ROE
9.3%
ROA
1.8%
ROIC
9.2%
ROCE
6.0%
ROC (Greenblatt)
34.4%
3Y ROIIC
−41.6%
Consistency
Years Profitable / 10Y
3
Valuation
Metric
Current
Earnings Multiples
P/E (TTM)
60.45
Forward P/E
18.41
P/E ex-NRI
15.85
Shiller P/E (CAPE)
—
Cash Flow Multiples
P/FCF
31.45
P/OCF
22.29
P/Owner Earnings
—
FCF Yield
3.19%
Enterprise Value Multiples
EV / EBIT
34.68
EV / Forward EBIT
35.26
EV / EBITDA
21.46
EV / Forward EBITDA
21.44
EV / Revenue
3.22
EV / Forward Revenue
3.32
Asset / Sales
P/S
2.45
P/B
5.44
P/Tangible Book
—
Growth-Adjusted
PEG
—
Capital Returns
Metric
Current
Dividends
Dividend Yield (TTM)
0.00%
Forward Dividend Yield
0.00%
3Y Dividend Growth
0.0%
Payout Ratio
0.00
5Y Yield on Cost
0.00%
Buybacks & Dilution
3Y Buyback Ratio
−1.20%
5Y Share Change
6.2%
Combined
Shareholder Yield
2.29%
Balance Sheet
Metric
Current
Leverage
Debt / Equity
2.18
Gross Debt / EBITDA
6.51
Cash / Debt
0.22
Equity / Assets
0.20
Coverage
Interest Coverage
3.63
Short-Term Liquidity
Current Ratio
0.88
Quick Ratio
0.67
Cash Ratio
0.23
Composite Scores
Piotroski F-Score
7
Altman Z-Score
0.81
Split History
Date
Split
2004-07-01
2:1
2002-12-06
2:1
2000-02-23
2:1
1993-04-14
2:1
1982-08-16
1.4006:1
Ex-date
Amount
Pay date
2017-11-27
$0.085
2017-12-12
2017-08-25
$0.085
2017-09-14
2017-06-01
$0.34
2017-06-22
2017-02-28
$0.34
2017-03-20
2016-12-01
$0.34
2016-12-20
2016-08-18
$0.34
2016-09-08
2016-05-20
$0.34
2016-06-07
2016-02-25
$0.34
2016-03-14
2015-11-13
$0.34
2015-12-03
2015-08-18
$0.34
2015-09-03
10 of 132
View allDate
Transcript
Type
2026-07-29
Q2 2026 Teva Pharmaceutical Industries Limited.. Earnings Call Transcript
Earnings Call
2026-07-07
Teva Pharmaceutical Industries Limited..To Discuss IL-15 Vitiligo Phase 1b 24 Week Efficacy Results Transcript
Corporate Presentation
2026-06-08
Teva Pharmaceutical Industries Limited.. at Goldman Sachs Healthcare Conference Transcript
Conference Presentations
2026-05-12
Teva Pharmaceutical Industries Ltd at Bank of America Global Healthcare Conference Transcript
Conference Presentations
2026-04-29
Q1 2026 Teva Pharmaceutical Industries Ltd Earnings Call Transcript
Earnings Call
2026-03-10
Teva Pharmaceutical Industries Ltd at Barclays Global Healthcare Conference Transcript
Conference Presentations
2026-01-28
Q4 2025 Teva Pharmaceutical Industries Ltd Earnings Call Transcript
Earnings Call
2026-01-13
Teva Pharmaceutical Industries Ltd at JPMorgan Healthcare Conference Transcript
Conference Presentations
2025-12-04
Teva Pharmaceutical Industries Ltd at Citi Global Healthcare Conference Transcript
Conference Presentations
2025-11-05
Q3 2025 Teva Pharmaceutical Industries Ltd Earnings Call Transcript
Earnings Call
10 of 55
5-Step DuPont Analysis
ROE %
9.68%
×
×
Net Margin %
4.08%
×
×
Operating Margin %
18.78%
Operating Income
$3.25B
÷
Revenue
$17.31B
×
Tax Burden
0.9972
Net Income
$706M
÷
Pretax Income
$708M
×
Interest Burden
0.2177
Pretax Income
$708M
÷
Operating Income
$3.25B
×
Asset Turnover
0.43
÷
Revenue
$17.31B
÷
Average Total Assets
$39.99B
Begin Total Assets
$40.13B
End Total Assets
$39.86B
×
Equity Multiplier
5.49
÷
Avg Total Assets
$39.99B
÷
Avg Stockholders Equity
$7.29B
Begin Equity
$6.83B
End Equity
$7.75B
Top institutional holders
Q2 2026| Holder | Shares | % Owned | Chg. shares | |
|---|---|---|---|---|
| BlackRock, Inc. | 63.9M | 5.49% | -1.2M | $2.16B |
| Harel Insurance Investments & Financial Services Ltd. | 48.1M | 4.13% | +2.2M | — |
| Phoenix Financial Ltd. | 42.9M | 3.69% | +156.0K | $1.45B |
| WCM INVESTMENT MANAGEMENT, LLC | 41.3M | 3.55% | +494.6K | $1.38B |
| Clal Insurance Enterprises Holdings Ltd | 40.6M | 3.49% | +2.1M | — |
| MENORA MIVTACHIM HOLDINGS LTD. | 39.9M | 3.42% | +228.0K | $1.35B |
| Migdal Insurance & Financial Holdings Ltd. | 38.9M | 3.34% | +1.0M | $1.32B |
| NORGES BANK | 32.3M | 2.77% | new | $1.09B |
| FMR LLC | 30.3M | 2.60% | -2.9M | $1.03B |
| Lingotto Investment Management LLP | 20.2M | 1.73% | -7.6M | $684.58M |
10 of 683
View allTop insider holdings
as reported| Insider | Shares held | % Owned | |
|---|---|---|---|
| Elstein AmirDirector | 2.1M | 0.1819% | $87.92M |
| Francis Richard DOfficer | 1.2M | 0.1011% | $48.87M |
| BARER SOL JDirector | 448.0K | 0.0385% | $18.59M |
| Hughes Eric AOfficer | 134.9K | 0.0116% | $5.60M |
| LIEBERMAN GERALD MDirector | 130.1K | 0.0112% | $5.40M |
| Crane Rosemary ADirector | 127.7K | 0.0110% | $5.30M |
| MIGNONE ROBERTODirector | 119.8K | 0.0103% | $4.97M |
| Nisen PerryDirector | 119.8K | 0.0103% | $4.97M |
| Satchi-Fainaro RonitDirector | 112.0K | 0.0096% | $4.65M |
| Sabag MarkOfficer | 80.8K | 0.0069% | $3.35M |
10 of 23
View allRecent insider activity
through Sep 18, 2026| Insider | Action | Shares | Date | |
|---|---|---|---|---|
| Savage BrianOfficer | Option Exercise (Rule 16b-3 Exempt) | +4.5K | $156.3K | Sep 18, 2026 |
| Savage BrianOfficer | Open-Market or Private Sale | -4.5K | $174.2K | Sep 18, 2026 |
| Savage BrianOfficer | Open-Market or Private Sale | -2.5K | $98.8K | Sep 18, 2026 |
| Savage BrianOfficer | Open-Market or Private Sale | -314 | $12.2K | Sep 18, 2026 |
| MIGNONE ROBERTODirector | Open-Market or Private Sale | -367.6K | $14.36M | Sep 18, 2026 |
| Weiss AmirOfficer | Open-Market or Private Sale | -6.9K | $261.2K | Aug 21, 2026 |
| Weiss AmirOfficer | Option Exercise (Rule 16b-3 Exempt) | +2.5K | $49.0K | Aug 21, 2026 |
| Weiss AmirOfficer | Open-Market or Private Sale | -2.5K | $94.1K | Aug 21, 2026 |
| Satchi-Fainaro RonitDirector | Open-Market or Private Sale | -415 | $15.5K | Aug 21, 2026 |
| Lippman EvanOfficer | Open-Market or Private Sale | -18.6K | $680.3K | Aug 17, 2026 |
10 of 784
View all